Related Experiment Video
Updated: Jul 1, 2026
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Translational landscape of cytokine-induced killer cell therapy: an analysis based on the Informa database
Yanni Zhang1, Han Sun1, Ye Yuan2
1Department of Radiotherapy, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
Abstract:
This study maps the global clinical trial landscape of cytokine-induced killer (CIK) cell therapy across malignancies and selected immune-related disorders, based on 199 interventional trials retrieved from the Informa database up to February 2026. Analysis reveals a rapidly expanding field dominated by early-phase studies, with China leading clinical translation and academic institutions as primary sponsors. Oncology trials are most frequent, particularly in lung cancer, leukemia, and hepatocellular carcinoma, while combinatorial strategies such as dendritic cell-CIK therapy or checkpoint inhibitor combinations are increasingly explored. Adjuvant and maintenance settings predominate over neoadjuvant applications, and emerging studies indicate potential extension into autoimmune and inflammatory diseases. These findings underscore the translational potential of CIK therapy, highlight evolving combination strategies, and reveal opportunities to optimize patient stratification, standardize cell preparation, and incorporate biomarker-guided approaches. Collectively, this landscape analysis highlights key trends shaping the future clinical development of CIK-based immunotherapy and informs strategic design considerations for advancing its integration into modern oncology and immunomodulatory treatments.
Insights
Cytokine-induced killer (CIK) cell therapy shows expanding global clinical trial use, especially in oncology. Future research focuses on novel combinations and optimizing CIK cell therapy for cancer and immune disorders.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Clinical Trials
Background:
- Cytokine-induced killer (CIK) cell therapy is an emerging immunotherapeutic approach.
- Clinical translation is rapidly expanding across various diseases.
Purpose of the Study:
- To map the global clinical trial landscape of CIK cell therapy.
- To identify trends in CIK cell therapy development for malignancies and immune disorders.
Main Methods:
- Analysis of 199 interventional trials from the Informa database up to February 2026.
- Systematic review of trial characteristics, including phase, sponsor, indication, and therapeutic strategy.
Main Results:
- The field is rapidly expanding, dominated by early-phase studies, with China leading clinical translation.
- Oncology trials are most frequent, particularly in lung cancer, leukemia, and hepatocellular carcinoma.
- Combinatorial strategies (e.g., dendritic cell-CIK, checkpoint inhibitors) and adjuvant/maintenance settings are increasingly explored, with potential in autoimmune diseases.
Conclusions:
- CIK cell therapy demonstrates significant translational potential in oncology and immunomodulatory treatments.
- Evolving combination strategies and emerging applications in autoimmune diseases highlight future directions.
- Opportunities exist to optimize patient stratification, cell preparation, and biomarker-guided approaches for CIK therapy.
